tetano
Editor, Senior Moderator
J Virol Methods
. 2024 May 4:114949.
doi: 10.1016/j.jviromet.2024.114949. Online ahead of print. SARS-CoV-2-specific T cell responses: a comparative analysis between QuantiFERON SARS-CoV-2, T-SPOT.COVID, and an in-house Omicron ELISpot
Willem A Mak[SUP] 1 [/SUP], Wendy Visser[SUP] 2 [/SUP], Johannes G M Koeleman[SUP] 2 [/SUP], David S Y Ong[SUP] 3 [/SUP]
Affiliations
Background: T cell immunity plays a pivotal role in mitigating the severity of coronavirus disease 2019 (COVID-19). Therefore, reliable functional T cell assays are required to evaluate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific T cell immunity in specific patient populations.
Methods: We recruited a cohort of 23 healthcare workers who received their bivalent Omicron BA.1 / ancestral mRNA booster vaccination or were infected with the Omicron variant at a median of 144 days and 227 days before blood collection, respectively. In this cohort, we compared the performances of two widely utilized commercial SARS-CoV-2 interferon-gamma release assays (IGRAs), i.e., QuantiFERON SARS-CoV-2 and T-SPOT.COVID, and an in-house designed Omicron enzyme-linked immunospot (ELISpot).
Results: The QuantiFERON SARS-CoV-2 and T-SPOT.COVID assays detected SARS-CoV-2 spike-specific T cells in 34.8% and 21.7% of participants, respectively. Moreover, our in-house designed ELISpot that included Omicron BA.4 and BA.5 full-spike peptides detected T cell responses in 47.8% of participants and was strongly associated with the T-SPOT.COVID.
Conclusion: The evaluation of SARS-CoV-2 T cell immunity using commercially accessible assays may yield disparate outcomes as results from different assays are not directly comparable. A specific Omicron ELISpot should be considered to assess Omicron-specific T cell immunity.
Keywords: COVID-19; ELISpot; IGRA; Immunity; SARS-CoV-2; T cells.
. 2024 May 4:114949.
doi: 10.1016/j.jviromet.2024.114949. Online ahead of print. SARS-CoV-2-specific T cell responses: a comparative analysis between QuantiFERON SARS-CoV-2, T-SPOT.COVID, and an in-house Omicron ELISpot
Willem A Mak[SUP] 1 [/SUP], Wendy Visser[SUP] 2 [/SUP], Johannes G M Koeleman[SUP] 2 [/SUP], David S Y Ong[SUP] 3 [/SUP]
Affiliations
- PMID: 38710307
- DOI: 10.1016/j.jviromet.2024.114949
Background: T cell immunity plays a pivotal role in mitigating the severity of coronavirus disease 2019 (COVID-19). Therefore, reliable functional T cell assays are required to evaluate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific T cell immunity in specific patient populations.
Methods: We recruited a cohort of 23 healthcare workers who received their bivalent Omicron BA.1 / ancestral mRNA booster vaccination or were infected with the Omicron variant at a median of 144 days and 227 days before blood collection, respectively. In this cohort, we compared the performances of two widely utilized commercial SARS-CoV-2 interferon-gamma release assays (IGRAs), i.e., QuantiFERON SARS-CoV-2 and T-SPOT.COVID, and an in-house designed Omicron enzyme-linked immunospot (ELISpot).
Results: The QuantiFERON SARS-CoV-2 and T-SPOT.COVID assays detected SARS-CoV-2 spike-specific T cells in 34.8% and 21.7% of participants, respectively. Moreover, our in-house designed ELISpot that included Omicron BA.4 and BA.5 full-spike peptides detected T cell responses in 47.8% of participants and was strongly associated with the T-SPOT.COVID.
Conclusion: The evaluation of SARS-CoV-2 T cell immunity using commercially accessible assays may yield disparate outcomes as results from different assays are not directly comparable. A specific Omicron ELISpot should be considered to assess Omicron-specific T cell immunity.
Keywords: COVID-19; ELISpot; IGRA; Immunity; SARS-CoV-2; T cells.